MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hepr.70190

Медицинская библиотека · Hepatology research : the official journal of the Japan Society of Hepatology · 2026

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Tada Fujimasa, Hiraoka Atsushi, Ohama Hideko, Tada Toshifumi, Hirooka Masashi, Kariyama Kazuya, Tani Joji, Atsukawa Masanori, Takaguchi Koichi, Itobayashi Ei, Fukunishi Shinya, Tsuji Kunihiko, Ishikawa Toru, Tajiri Kazuto, Tanaka Hironori, Toyoda Hidenori, Ogawa Chikara, Nishimura Takashi, Hatanaka Takeshi, Kakizaki Satoru, Kawata Kazuhito, Naganuma Atsushi, Kosaka Hisashi, Matono Tomomitsu, Ueda Yoshihide, Kuroda Hidekatsu, Yata Yutaka, Nishikawa Hiroki, Imai Michitaka, Aoki Tomoko, Ochi Hironori, Okamura Jumpei, Tamai Hideyuki, Nakamura Shinichiro, Nakamura Yoshiko, Yoshida Osamu, Nouso Kazuhiro, Morishita Asahiro, Itokawa Norio, Okubo Tomomi, Arai Taeang, Tsutsui Akemi, Nagano Takuya, Tanaka Kazunari, Koshiyama Yuichi, Kanayama Yuki, Noritake Hidenao, Komatsu Shohei, Fukumoto Takumi, Matsuura Takanori, Kim Soo Ki, Enomoto Hirayuki, Matsui Kosuke, Kaibori Masaki, Hiasa Yoichi, Kudo Masatoshi, Kumada Takashi, Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group

СтатьяПеревод в очереди

Аннотация

AIM: Atezolizumab plus bevacizumab (Atez/Bev) in unresectable hepatocellular carcinoma (uHCC) is a standard first-line therapy, but bleeding-related adverse events (BL-AEs) remain clinically concerning, particularly in real-world patients with advanced tumors, portal hypertension, or undergoing antithrombotic therapy (ATT). We aimed to evaluate whether ATT increases bleeding risk, identify pretreatment factors associated with BL-AEs, and assess the impact of bleeding on progression-free survival (PFS) and overall survival (OS) in patients with uHCC treated with Atez/Bev.

METHODS

This multicenter retrospective study included 981 patients with uHCC treated with Atez/Bev. BL-AEs were identified by clinical assessment, imaging, or endoscopy. Predictors of BL-AEs were analyzed using logistic regression. Survival outcomes were compared by Kaplan-Meier method, with inverse probability weighting (IPW) applied to adjust for baseline imbalances.

RESULTS

BL-AEs occurred in 102 patients (10.4%) and led to treatment discontinuation in 2.7% patients. Independent predictors of BL-AEs included advanced tumor burden components, such as Vp ≥ 3 portal vein invasion and extrahepatic metastasis. Neither ATT nor portal hypertension-related factors were associated with bleeding risk. PFS did not differ between groups, whereas OS was significantly shorter in the BL group before IPW adjustment than after IPW adjustment.

CONCLUSIONS

During Atez/Bev therapy, BL-AEs were primarily associated with advanced tumor burden rather than with ATT or baseline portal hypertension-related factors. Although BL-AEs were associated with poorer OS, this should be interpreted cautiously, as bleeding may reflect aggressive tumor biology rather than a direct mortality cause. Careful monitoring for bleeding complications may be required in patients with advanced tumor burden receiving Atez/Bev.

Для цитирования: Tada Fujimasa, Hiraoka Atsushi, Ohama Hideko, Tada Toshifumi, Hirooka Masashi, Kariyama Kazuya, Tani Joji, Atsukawa Masanori, Takaguchi Koichi, Itobayashi Ei, Fukunishi Shinya, Tsuji Kunihiko, Ishikawa Toru, Tajiri Kazuto, Tanaka Hironori, Toyoda Hidenori, Ogawa Chikara, Nishimura Takashi, Hatanaka Takeshi, Kakizaki Satoru, Kawata Kazuhito, Naganuma Atsushi, Kosaka Hisashi, Matono Tomomitsu, Ueda Yoshihide, Kuroda Hidekatsu, Yata Yutaka, Nishikawa Hiroki, Imai Michitaka, Aoki Tomoko, Ochi Hironori, Okamura Jumpei, Tamai Hideyuki, Nakamura Shinichiro, Nakamura Yoshiko, Yoshida Osamu, Nouso Kazuhiro, Morishita Asahiro, Itokawa Norio, Okubo Tomomi, Arai Taeang, Tsutsui Akemi, Nagano Takuya, Tanaka Kazunari, Koshiyama Yuichi, Kanayama Yuki, Noritake Hidenao, Komatsu Shohei, Fukumoto Takumi, Matsuura Takanori, Kim Soo Ki, Enomoto Hirayuki, Matsui Kosuke, Kaibori Masaki, Hiasa Yoichi, Kudo Masatoshi, Kumada Takashi, Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group. Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.. Hepatology research : the official journal of the Japan Society of Hepatology. 2026. DOI: 10.1111/hepr.70190.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.